Novartis and Alnylam to develop RNAi therapeutics for pandemic flu
This collaboration is in addition to the collaboration formed by the two companies in September 2005, and significantly reinforces the development program for pandemic flu announced by Alnylam
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.